Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q4 2025 value amounting to $3.8 million.

  • Vanda Pharmaceuticals' Cost of Revenue rose 4799.23% to $3.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.0 million, marking a year-over-year increase of 1529.08%. This contributed to the annual value of $13.0 million for FY2025, which is 1529.08% up from last year.
  • Vanda Pharmaceuticals' Cost of Revenue amounted to $3.8 million in Q4 2025, which was up 4799.23% from $3.0 million recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Cost of Revenue peaked at $6.8 million during Q3 2021, and registered a low of $2.6 million during Q3 2024.
  • Its 5-year average for Cost of Revenue is $4.5 million, with a median of $3.7 million in 2025.
  • Its Cost of Revenue has fluctuated over the past 5 years, first tumbled by 5153.48% in 2023, then soared by 4799.23% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Cost of Revenue stood at $6.2 million in 2021, then rose by 0.03% to $6.2 million in 2022, then plummeted by 44.53% to $3.5 million in 2023, then dropped by 25.14% to $2.6 million in 2024, then skyrocketed by 47.99% to $3.8 million in 2025.
  • Its Cost of Revenue was $3.8 million in Q4 2025, compared to $3.0 million in Q3 2025 and $2.7 million in Q2 2025.